You are here
P&T December 2016
A final rule from the Centers for Medicare and Medicaid Services has added pharmacy requirements for long-term-care facilities that put more responsibility on pharmacists but don’t address conflict-of-interest concerns.
Rituximab can cause late-onset neutropenia that may result in serious life-threatening complications. The author describes the pathophysiology, incidence, and management of this adverse reaction and presents two case histories.
The authors review the evidence behind the use of thrombolytic therapy in patients with massive or submassive pulmonary embolism. Concurrent heparin therapy and the management of bleeding episodes are also discussed.
Short on funds and with no therapeutics or vaccines in sight, U.S. health officials are scrambling to prepare for a protracted fight with Zika virus and the mosquitoes that carry it. In this article, the author focuses on the arrival of Zika in the U.S.
We review several key sessions from the European Society for Medical Oncology’s annual congress, including those on emerging immunotherapies for melanoma and non–small-cell lung cancer and on treatments for renal, ovarian, and breast cancer.
Preventing fatal PCA adverse events
Medicare names plans for Part D MTM demo
Approvals, new indications, regulatory activities, and more
Lisinopril oral solution (Qbrelis) for the treatment of hypertension, heart failure, and acute myocardial infarction; etanercept-szzs (Erelzi) for multiple autoimmune disorders; and lumacaftor/ivacaftor (Orkambi) for cystic fibrosis
Daclatasvir (Daklinza) for chronic hepatitis C infection